Clinical Trial Update: A Study of CP-751,871 in Patients With Recurrent Squamous Head and Neck Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study of CP-751,871 in recurrent squamous cell carcinoma of the head and neck has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• CP-751,871 (dalotuzumab)

Snippet

Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Conditions: Head and Neck Cancer | Phase 2 | Status: TERMINATED